The personalized medicine coalition: Goals and strategies

American Journal of PharmacoGenomics

Volumn 5, Issue 6, 2005, Pages 345-355

  Abrahams, Edward ^a   Ginsburg, Geoffrey S ^b   Silver, Mike ^c  

^a Personalized Medicine Coalition   (United States)

^b DUKE UNIVERSITY   (United States)

^c Feinstein Kean Healthcare   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; MERCAPTOPURINE; RETINOIC ACID; TAMOXIFEN; TRASTUZUMAB; WARFARIN;

ACUTE GRANULOCYTIC LEUKEMIA; ATHEROSCLEROSIS; BLOOD CLOTTING DISORDER; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CONSENSUS; CURRICULUM; DECISION SUPPORT SYSTEM; DRUG INDUSTRY; ECONOMICS; ELECTRONICS; GENETICS; HEALTH CARE INDUSTRY; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HEALTH INSURANCE; HUMAN; HYPERTENSION; INSURANCE; INTERPERSONAL COMMUNICATION; MEDICAL EDUCATION; MEDICAL ETHICS; MEDICAL RECORD; MEDICAL SCHOOL; MEDICINE; MEDICOLEGAL ASPECT; MELANOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; PHARMACOGENETICS; PHYSICIAN; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; SOCIAL ASPECT; TRAINING;

COMMUNICATION; DECISION SUPPORT SYSTEMS, CLINICAL; DELIVERY OF HEALTH CARE; DRUG INDUSTRY; HEALTH PERSONNEL; HEALTH PLANNING ORGANIZATIONS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; PATIENT EDUCATION; PHARMACOGENETICS; PHYSICIAN'S ROLE; PRIVATE SECTOR; PUBLIC SECTOR; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 28944433632     PISSN: 11752203     EISSN: 11752203     Source Type: Journal    
DOI: 10.2165/00129785-200505060-00002     Document Type: Review

References (50)

1. Stearns V, Davidson NE, Flockhart D. Pharmacogenetics in the treatment of breast cancer. Pharmacogenetics 2004; 4: 143-53
2. Marsh S, McLeod H. Cancer pharmacogenetics. Br J Cancer 2004; 90: 8-11
3. Webster A, Martin P, Lewis G, et al. Integrating pharmacogenetics into society: in search of a model. Nat Rev Genet 2004; 5: 663-9
4. Personalized Medicine Coalition: news and events [online]. Available from URL: http://www.personalizedmedicinecoalition.org/newsevents/news.php [Accessed 2005 Sep 1]
5. Genomics and population health: United States, 2003. Atlanta (GA): Centers for Disease Control and Prevention, Office of Genomics and Disease Prevention, 2004 [online]. Available from URL: http://www.cdc.gov/genomics/ activities/ogdp/2003.htm [Accessed 2005 Sep 1]
6. Pharmacogenetics Research Network. Goals for the Pharmacogenetics Research Network [online]. Available from URL: http://www.nigms.nih.gov/ Initiatives/PGRN/Background/Goals.htm [Accessed 2005 Sep 1]
7. Guidance for industry: pharmacogenomic data submissions. Rockville (MD): US Department of Health and Human Services, US Food and Drug Administration, March 2005 [online]. Available from URL: http://www.fda.gov/cder/guidance/ 6400fnl.pdf [Accessed 2005 Sep 1]
8. Our inheritance, our future: realising the potential of genetics. London: National Health Service, Department of Health, 2003 [online]. Available from URL: http://www.dh.gov.uk/assetRoot/04/01/92/39/04019239.pdf [Accessed 2005 Sep 1]
9. Duke Institute for Genome Sciences and Policy [online]. Available from URL: http:// www.genome.duke.edu [Accessed 2005 Sep 1]
10. Genetics and Public Policy Center, Johns Hopkins University [online]. Available from URL: http://www.dnapolicy.org [Accessed 2005 Sep 1]
11. Burton H. Addressing genetics, delivering health: a strategy for advancing the dissemination and application of genetics knowledge throughout our health professions. Cambridge: Public Health Genetics Unit, 2003 [online]. Available from URL: http://www.phgu.org.uk/resources/educ_project/ addressing_genet-ics_full_300903.pdf [Accessed 2005 Sep 1]
12. Suther S, Goodson P. Barriers to the provision of genetic services by primary care physicians: a systematic review of the literature. Genet Med 2003; 5 (2): 70-6
13. Wideroff L, Thomas VS, Greene MH, et al. A hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians. J Med Genet. Epub 2005 Mar 22
14. Elliott VS. Genetic testing issues land in primary care practices. Am Med News 2004 Nov 8 [online]. Available from URL: http://www.ama-assn.org/ amednews/2004/11/08/hll11108.htm [Accessed 2005 Sep 1]
15. Pharmaceutical industry profile 2005. From laboratory to patient: pathways to biopharmaceutical innovation. Washington, DC: Pharmaceutical Research and Manufacturers of America, 2005 [online]. Available from URL: http://www.phrma.org/publications/publications//2005-03-17.1143.pdf [Accessed 2005 Sep 1]
16. Gollust SE, Hull SC, Wilfond BS. Limitations of direct-to-consumer advertising for clinical genetic testing. JAMA 2002; 288 (14): 1762-7
17. Physicians slow to adopt IT for patient care [editorial]. Drug Benefit Trends 2004; 16 (11): 535
18. Koppel R, Metlay JP, Cohen A, et al. Role of computerized physician order entry systems in facilitating medication errors. JAMA 2005; 293: 1197-203
19. Javitt JC, Steinberg G, Locke T, et al. Using a claims data-based sentinel system to improve compliance with clinical guidelines: results of a randomized prospective study. Am J Manag Care 2005; 11 (2): 93-102
20. Bush pushes computerized medical records. Associated Press 2005 Jan 27 [online]. Available from URL: http://msnbc.msn.com/id/6876192/ [Accessed 2005 Sep 1]
21. What do Newt Gingrich and Hillary Clinton agree on? Fed money for health IT. InformationWeek 2005 May 11 [online]. Available from URL: http://informa-tionweek.com/story/showArticle.jhtml?articleID=163101097 [Accessed 2005 Sep 1]
22. In unexpected Medicare benefit, U.S. will offer doctors free electronic records system. N Y Times 2005 Jul 21; Sect. A: 14 (col. 1)
23. Schoonmaker MM, Bernhardt BA, Holtzman NA. Factors influencing health insurers' decisions to cover new genetic technologies. Int J Technol Assess Health Care 2000; 16 (1): 178-89
24. The Lewin Group. The value of diagnostics: innovation, adoption and diffusion into health care. 2005 Jul [online]. Available from URL: http://www.advamed.org/publicdocs/thevalueofdiagnostics.pdf [Accessed 2005 Sep 1]
25. Drug-diagnostic co-development concept paper. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, 2005 Apr [online]. Available from URL: http://www.fda.gov/cder/genomics/ pharmacoconceptfn.pdf [Accessed 2005 Sep 1]
26. Lesko LJ, Woodcock J. Pharmcogenomic-guided drug development: regulatory perspective. Pharmacogenomics J 2002; 2: 20-4
27. Issa AM. Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges. Pharmacogenomics 2003; 4 (5): 647-55
28. Ratner ML. Pharmacogenomic data and labeling: a less-safe harbor for existing drugs? Windhover's Update 2003 May 25 [online]. Available from URL: http://www.windhover.com/update/05252003/2003800094.htm [Accessed 2005 Sep 1]
29. Feigal DW, Gutman S. Drug development, regulation, and genetically guided therapy. In: Rothstein MA, editor. Pharmacogenomics: social, ethical, and clinical dimensions. Hoboken (NJ): John Wiley & Sons, 2003: 99-108
30. Roses AD. Pharmacogenetics and future drug development and delivery. Lancet 2000; 355: 1358-61
31. Robertson JA, Brody B, Buchanan A, et al. Pharmacogenetic challenges for the health care system: genetically based drug prescribing could decrease overall health costs and fuel new drug development. Health Aff 2002; 21 (4): 155-67
32. Phillips KA, Veenstra DL, Sadee W. Implications of the genetics revolution for health services research: pharmacogenomics and improvements in drug therapy. Health Serv Res 2000; 35 (5): 1-12
33. Phillips KA, Veenstra DL, Ramsey SD, et al. Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. Am J Manag Care 2004; 10: 425-32
34. Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci 2000 Sep 14; 2 (3): article 29 [online]. Available from URL: http://www.aapspharmsci.org/articles/ps0203/ps020329/ ps020329.pdf [Accessed 2005 Sep 1]
35. Nuffield Council on Bioethics. Pharmacogenetics: ethical issues. London: Nuffield Council on Bioethics, 2003 [online]. Available from URL: http://www.nuffieldbioethics.org/fileLibrary/pdf/pharmacogenetics_report.pdf [Accessed 2005 Sep 1]
36. Epps P. Policy before practice. Am J Pharmacogenomics 2003; 3 (6): 405-18
37. Breckenridge A, Lindpaintner K, Lipton P. Pharmacogenetics: ethical problems and solutions. Nat Rev Genet 2004; 5: 676-80
38. Vaszar LT, Cho MK, Raffin TA. Privacy issues in personalized medicine. Pharmacogenomics 2003; 4 (2): 107-12
39. Freund CL, Wilfond BS. Emerging ethical issues in pharmacogenomics: from research to clinical practice. Am J Pharmacogenomics 2002; 2 (4): 273-81
40. Moldrup C. Ethical, social and legal implications of pharmacogenomics: a critical review. Community Genet 2001; 4 (4): 204-14
41. Zick CD, Mathews CJ, Roberts JS, et al. Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior. Health Aff 2005; 24 (2): 483-90
42. Hall MA, Rich SS. Laws restricting health insurers' use of genetic information: impact on genetic discrimination. Am J Hum Genet 2000 Jan; 66 (1): 293-307
43. America's Health Insurance Plans. Use of genetic information [online]. Available from URL: http://www.ahip.org/content/default.aspx?.bc=39|341|326 [Accessed 2005 Sep 1]
44. Collins FS, McKusick VA. Implications of the human genome project for medical science. JAMA 2001; 285 (5): 540-4
45. Frueh FW, Gurwitz D. From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics 2004; 5 (5): 571-9
46. Burton H, Shuttleworth A. Genetics education for pharmacists. Pharm J 2003; 270: 84-5
47. Centers for Disease Control and Prevention (CDC) awards funds for genetics programs [online]. Released 2001 Oct 18. Available from URL: http://www.cdc.gov/genomics/activities/fund2001.htm [Accessed 2005 Apr 30]
48. Rothstein MA, Hornung CA. Public attitudes toward pharmacogenomics. In: Rothstein MA, editor. Pharmacogenomics: social, ethical, and clinical dimensions. Hoboken (NJ): John Wiley & Sons, 2003: 3-28
49. Wideroff L, Vadaparampil ST, Breen N, et al. Awareness of genetic testing for increased cancer risk in the year 2000 National Health Interview Survey. Community Genet 2003; 6 (3): 147-56
50. Wideroff L, Freedman AN, Olson L, et al. Physician use of genetic testing for cancer susceptibility: results of a national survey. Cancer Epidemiol Biomarkers Prev 2003; 12: 295-303